Upregulation of glucocorticoid receptor‐mediated glucose transporter 4 in enzalutamide‐resistant prostate cancer

Enzalutamide (Enz) is a second‐generation androgen receptor (AR) antagonist for castration‐resistant prostate cancer (CRPC) therapy, and it prolongs survival time in these patients. However, during Enz treatment, CRPC patients usually acquire resistance to Enz and often show cross‐resistance to othe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Sci
Autores principales: Hoshi, Seiji, Meguro, Satoru, Imai, Hitomi, Matsuoka, Yuta, Yoshida, Yuki, Onagi, Akihumi, Tanji, Ryo, Honda‐Takinami, Ruriko, Matsuoka, Kanako, Koguchi, Tomoyuki, Hata, Junya, Sato, Yuichi, Akaihata, Hidenori, Kataoka, Masao, Ogawa, Soichiro, Kojima, Yoshiyuki
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8088914/
https://ncbi.nlm.nih.gov/pubmed/33619826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14865
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares